drugset / Trial / NCT01526278

Pharmacokinetics of Maxmarvil® in Healthy Postmenopausal Women

NCT01526278

Phase 1 Completed 18 enrolled Yuyu Pharma, Inc.
NaSingle-groupOpen-labelTreatment

Summary

This study will evaluate clinical safety and pharmacokinetics of Maxmarvil® in healthy postmenopausal women

Timeline

Start
2011-10
Primary completion
2012-07
Completion
2012-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Alendronic Acid Small molecule 5 mg Oral
Subject Calcitriol Small molecule 0.5 ug Oral

Indications